Project Grant HT94252410194
Award Date 4/1/24
Completion Date 3/31/26
Dollars Obligated $797K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Gainesville, FL 32611, USA
Similar Awards
- The University of North Carolina at Chapel Hill will use a $777,500 Project Grant from the Defense Health Agency to support research aimed at reducing expression of TDP-43 protein in amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease. The grant was awarded on April 15, 2023 under the Military Medical Research and Development program (CFDA 12.420). Through April 14, 2025, UNC-Chapel Hill researchers will investigate medical solutions for ALS at the project site in Chapel...
- The Defense Health Agency awarded a $929,948 Project Grant to The Washington University in St. Louis, Missouri to support the research project "TARGETING TDP-43 MITOCHONDRIAL MISLOCALIZATION IN ALS". This grant is funded through the Military Medical Research and Development program (CFDA 12.420), which supports biomedical research aimed at improving the health and care of military service members, veterans, and their families. The research project will investigate mitochondrial...
- This federal Project Grant award of $1,392,575.00 from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) supports a project by Sola Biosciences, Inc. to develop a protein folding-based gene therapy targeting TDP-43 for the treatment of amyotrophic lateral sclerosis (ALS). The project aims to transform healthcare for military service members and the public through innovative biomedical research, with a focus on developing medical solutions...
- This Project Grant award of $894,330.00 from the U.S. Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) is funding research conducted by the University of Miami to investigate "Targeting Axonal Regeneration Pathways as a Therapeutic Approach to ALS." The project aims to transform healthcare for military service members and the broader public by advancing biomedical research into innovative medical solutions for critical health challenges. The award...
- This $2,536,839 Project Grant award from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) supports advanced biomedical research by New York University School of Medicine to develop a novel therapeutic strategy for treating amyotrophic lateral sclerosis (ALS). The research aims to target the RAGE/DIAPH1 axis, a promising approach for ALS therapeutic development. This 3-year grant, awarded on August 1, 2025, will fund cutting-edge scientific...
- The University of Massachusetts Medical School was awarded a $1,005,000 Project Grant from the U.S. Department of Defense's Military Medical Research and Development program (CFDA 12.420) to develop pad inhibitors for the treatment of amyotrophic lateral sclerosis (ALS). The award, which commenced on September 30, 2024, will support research activities through September 29, 2026. The Medical School's Grants and Contracts Administration division, doing business as UMms, will lead the project...
- This $749,995 Project Grant awarded by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) supports the development of gene therapies for the targeted degradation of the TDP-43 protein to treat Amyotrophic Lateral Sclerosis (ALS) at Macquarie University in Australia. The project aims to advance therapeutic approaches for this neurodegenerative disease. Macquarie University, a non-profit educational institution, will conduct the research over a...
- This $586,740 Project Grant awarded by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) will fund research by the Als Therapy Development FND, doing business as A L S Therapy Development Institute, to investigate the pharmacological inhibition of TRAF2- and NCK-interacting kinase (TNIK) as a potential treatment for amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease. The grant will support the non-profit organization's...
- The Defense Health Agency awarded a $659,922 Project Grant to Macquarie University in Australia under the Military Medical Research and Development program (CFDA 12.420). The grant funds a gene therapy research project aimed at developing a treatment for delaying the onset of Amyotrophic Lateral Sclerosis (ALS) through nuclear TDP-43 supplementation. The research will be conducted at Macquarie University over a 2-year period from September 2025 to September 2027. This project grant is part of...
- The federal Project Grant award titled "TARGETING TDP-43 PROTEIN DYNAMICS IN TRAUMA-ASSOCIATED ALZHEIMER'S DISEASE RELATED DEMENTIA" is funded by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420). The award, totaling $999,965.00, was granted to Yale University on January 15, 2025 for a project period ending on January 14, 2028. The funding supports advanced biomedical research aimed at transforming healthcare for military service...